Form 4 for STLN Starling Oncology, Inc.
Accepted 2021-11-16 00:00:00 ET · period of report 2021-11-12 · accession 0001104659-21-140230 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-11-16 | 2021-11-12 | STLN | BARASCH RICHARD A | Dir | D - Sale to Iss | — | -14.9K | 85.1K | -15% | — |
| D | 2021-11-16 | 2021-11-12 | STLN | BARASCH RICHARD A | Dir | C - Cnv Deriv | — | +100.0K | 100.0K | New | — |
| D | 2021-11-16 | 2021-11-12 | STLN | BARASCH RICHARD A | Dir | C - Cnv Deriv | — | -100.0K | 0 | -100% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-11-12 | D | D | 14,887 | — | 85,113 | D | — | — | (F1) The shares of Class B common stock converted into shares of the Issuer's Class A common stock on a one for basis in connection with the Business Combination (as deifned below), and have no expiration date. (F2) On November 12, 2021, pursuant to that certain Agreement and Plan of Merger, dated as June 28, 2021, by and among DFP Healthcare Acqusitions Corp. ("DFP"), Orion Merger Sub I, Inc. ("First Merger Sub"), Orion Merger Sub II, LLC ("Second Merger Sub"), and TOI Parent, Inc. ("Old TOI"), First Merger Sub merged into Old TOI, with Old TOI being the surivivng corporation then Old TOI merged into Second Merger Sub, with Second Merger Sub being the surviving entity and a wholly owned subsidiary of DFP, which then changed its name to The Oncology Institute, Inc. (such transactions, collectively, the "Business Combination"). In connection with the Business Combination, the Class A common stock was converted to Common Stock of the Issuer, pursuant to a reclassification exempt under Rule 16b-7. |
| 2 | Common | Common Stock | 2021-11-12 | C | A | 100,000 | — | 100,000 | D | — | — | (F1) The shares of Class B common stock converted into shares of the Issuer's Class A common stock on a one for basis in connection with the Business Combination (as deifned below), and have no expiration date. (F2) On November 12, 2021, pursuant to that certain Agreement and Plan of Merger, dated as June 28, 2021, by and among DFP Healthcare Acqusitions Corp. ("DFP"), Orion Merger Sub I, Inc. ("First Merger Sub"), Orion Merger Sub II, LLC ("Second Merger Sub"), and TOI Parent, Inc. ("Old TOI"), First Merger Sub merged into Old TOI, with Old TOI being the surivivng corporation then Old TOI merged into Second Merger Sub, with Second Merger Sub being the surviving entity and a wholly owned subsidiary of DFP, which then changed its name to The Oncology Institute, Inc. (such transactions, collectively, the "Business Combination"). In connection with the Business Combination, the Class A common stock was converted to Common Stock of the Issuer, pursuant to a reclassification exempt under Rule 16b-7. |
| 3 | Derivative | Class B Common Stock | 2021-11-12 | C | D | 100,000 | — | 0 | D | — · — to — | 100,000 Class A Common Stock | (F1) The shares of Class B common stock converted into shares of the Issuer's Class A common stock on a one for basis in connection with the Business Combination (as deifned below), and have no expiration date. |